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Introduction
Pertussis or whooping cough, caused by Bordetella 
pertussis, is a highly contagious and vaccine-preventable 
bacterial infection that affects all susceptible individuals, 
regardless of age. Although it is a notifiable disease in 
South Africa, it is believed to be an uncommon condition. 
According to the World Health Organization (WHO), no cases 
were reported in South Africa in the period 2004–2008.1 
However, according to another source, three cases were 
reported in 2007.2 A recent resurgence of pertussis cases 
has been reported mainly from developed countries, yet the 
real burden is believed to be in the developing nations.3
Definitive diagnosis of pertussis is challenging. This article 
describes an outbreak of pertussis in Bloemfontein from 
April 2008 to March 2009.
Methods
This is a case series of children diagnosed with pertussis. 
The clinical case definition included any of the following 
symptoms: cough of at least two weeks’ duration, 
paroxysms of coughing, inspiratory whoop, post-tussive 
vomiting, or apnoea in young infants.4
Dry nasal swabs were taken with a Dacron® swab and 
referred by the local National Health Laboratory Services 
(NHLS) medical microbiology laboratory to the NHLS 
central referral laboratory in Johannesburg for a Bordetella 
polymerase chain reaction (PCR) test. Specimens obtained 
from patients in the private sector were analysed by private 
laboratories. The sensitivity, specificity, positive predictive 
value and negative predictive value for the PCR have been 
reported as 93.5%, 97.1%, 84.3% and 98.9%, respectively.5
A child with clinical features of pertussis and a positive 
PCR result was regarded as a definite case of pertussis and 
notified to the appropriate authorities. Clinical data were 
collected of each case.
Ethics approval for the study was obtained from the Ethics 
Committee of the Faculty of Health Sciences, University of 
the Free State (ETOVS number 143/08).
Results
In the 12-month period, 97 swabs from the public sector and 
an unknown number of swabs from the private sector were 
sent for Bordetella PCR analysis. Twelve specimens were 
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either unsuitable for analysis or the result was equivocal, 
and 70 had negative results. Fifteen specimens yielded 
positive results (15 of 85 suitable specimens, 17.6%) for B. 
pertussis and none for B. parapertussis. Three confirmed 
positive results were reported in the private sector cases.
In total, 18 confirmed cases of pertussis were therefore 
detected. Twelve patients were female and six were 
male. All patients lived in Bloemfontein or the immediate 
surrounding areas. All cases were seen by doctors working 
in the public sector, supervised by a paediatric consultant. 
The cases diagnosed in the private sector were seen by one 
paediatrician. A predominance of cases was noted during 
the autumn and winter months, while three cases occurred 
during spring or early summer (Figure 1). The ages of the 
children ranged between five weeks and 31 months (Table 
I). Twelve (66.7%) children were younger than six months 
of age.
According to the children’s clinical history, the duration 
of cough ranged from one day up to two weeks. No child 
had been coughing for longer than two weeks at initial 
presentation. On examination, post-tussive vomiting, stac-
cato cough, apnoeic episodes, cyanotic episodes and 
coughing spells were most commonly observed. Only five 
children presented with an inspiratory whoop, one child had 
convulsions, and none of the children had subconjunctival 
haemorrhages.
Eight (44.4%) children had total white cell counts above 
20.0 x 109/l, of which seven had high lymphocyte counts 
(either above 17.0 x 109/l or 50% or more of the total white 
cell count).
Fifteen (83.3%) children required hospitalisation, of 
whom five had to be admitted to the intensive care unit 
(ICU). The latter were all aged nine weeks or younger. 
Complications encountered included pneumonia with 
hypoxia, pneumothorax, myocarditis and prerenal failure 
with hypernatraemia. The duration of ventilation, ICU stay 
and total hospital stay are shown in Table II.
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All public sector patients were treated with oral erythromycin 
at a dosage of 15–25 mg/kg per dose in four daily doses for 
14 days. All immediate contacts were given erythromycin 
prophylaxis. Neither clarithromycin nor azithromycin, the 
preferred antibiotics for the treatment of pertussis, was 
available in the public sector. Children from the private 
sector were also treated with erythromycin (the reason for 
this was not given).
Fourteen (77.8%) of the 18 children had an appropriate 
vaccination status for their age. Of the other four, one child, 
aged four and a half months, had never been immunised, 
while another child of seven months had missed the 
third diphtheria, pertussis and tetanus (DPT) dose. The 
vaccination status of two children was unknown.
A “prevaccinated” child is one who has not yet received all 
three initial doses of the pertussis vaccine (incompletely 
vaccinated or too young to be fully vaccinated), or who is 
younger than 18 weeks of age. It takes a month after the 
last vaccine to reach an adequate antibody level.6,7 Twelve 
(66.7%) children were prevaccinated or incompletely 
vaccinated infants, while six (33.3%) were fully vaccinated. 
Of the 12 prevaccinated children, five had not yet received 
any pertussis vaccine, while the other seven had received 
one or two vaccinations shortly before they became ill. 
Three of the five babies that had not received any pertussis 
vaccine required ICU admission. The vaccination coverage 
Table I: Age distribution of pertussis cases
Age of patients Number of cases (n = 18) %
5 weeks 4 22.2
6 weeks 2 11.1
6–9 weeks 2 11.1
11–12 weeks 3 16.7
4 months 1 5.6
6 months 3 16.7
11 months 1 5.6
14 months 1 5.6















































Figure 1: Distribution of the monthly incidence of pertussis, April 2008 – 
March 2009.
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of DPT in the Motheo district of the Free State at the time of 
the outbreak was just below 90% (personal communication, 
Expanded Programme on Immunisation officer, Free State 
Department of Health).
In seven (38.9%) patients, a history of coughing in an adult 
family member, such as a parent, relative or grandparent, 
was reported. Owing to cost constraints, we did not 
investigate any of the contacts.
The cost analysis based on the length of hospital stay 
(ward and/or ICU) is expounded in Table III. Of the 15 cases 
diagnosed in the public sector, only two patients received 
ambulatory care. The other 13 children spent a total of 235 
days in the hospital: 147 days in the general wards and 88 
days in the ICU. The five infants who required intensive 
care were ventilated for a total of 63 days. One of the three 
children in the private sector received ambulatory care, 
while the other two spent a total of 22 days in a general 
paediatric ward. The mean total cost for each hospitalised 
case of pertussis was over R20 000. This amount did not 
include the laboratory investigations, medication and 
additional expenses for the parents, such as transport and 
absence from work. The amounts given have been rounded 
off to the nearest rand.
A brief summary of the infants treated in the ICU is given 
below (see also Table II).
Case 9: The infant (aged six weeks) had not yet been 
vaccinated and was not human immunodeficiency virus- 
(HIV) exposed. The child had a one-day history of cough 
and apnoeic episodes with cyanosis at home. The father, a 
paramedic, gave mouth-to-mouth resuscitation and rushed 
the child 60 km to Bloemfontein. She also had right upper 
lobe pneumonia.
Case 10: The infant (aged five weeks) had not yet been 
vaccinated, and was HIV exposed but uninfected. This child 
was initially admitted to the general ward with a diagnosis 
of Pneumocystis pneumonia, possible pertussis. His total 
white cell count at admission was 57.99 x 109/l (normal for 
five weeks 5–19.50 x 109/l), and his lactate dehydrogenase 
levels (LDH) were 733 U/l (normal range 180–430 U/l). 
Cyanotic spells were noted after five days of hospitalisation. 
His condition deteriorated and he was admitted to the ICU 
on day 9 of his illness. The white cell count increased to 
72.49 x 109/l after one week, and he developed myocarditis 
and right upper lobe collapse.
Case 11: The infant (aged five-and-a-half weeks) had not 
yet been vaccinated and was not exposed to HIV. This baby 
was difficult to ventilate, requiring high-frequency oscillation 
and developing bilateral pneumothoraces, convulsions and 
nosocomial Klebsiella septicaemia. Oxygen dependence 
persisted for 30 days after ventilation was ended.
Case 16: The infant (aged nine weeks) was HIV exposed, 
had received nevirapine after birth (local policy at the time), 
was breastfed and had received supplemental formula 
feeds, according to information obtained from the mother. 
The baby was intubated in the emergency department and 
admitted to ICU. Treatment for presumed Pneumocystis 
pneumonia was started. An increased LDH level of 1 047 U/l 
was observed. The cue to pertussis was a white cell count 
of 26.0 x 109/L, with a lymphocyte predominance of 13.8 x 
109/l (normal for nine weeks 1.2–3.4 x 109/L). The clinical 
diagnosis of pertussis was confirmed by PCR testing eight 
days after admission. Nosocomial infections developed, 
which included Klebsiella from a tracheal aspirate, 
Acinetobacter from a blood culture and Enterococcus 
faecium from a urine specimen. The HIV-PCR test was 
positive and the child was started on antiretroviral treatment 
during hospitalisation.
Case 17: This infant (aged nine weeks) was born at 28 
weeks’ gestation with a birth weight of 1  050 g. He was 
admitted to the neonatal ICU, ventilated for four days 
and discharged well at six weeks of age. The baby had 
not yet been vaccinated. He was readmitted three weeks 
later with apnoea attacks and convulsions and developed 
bilateral pneumothoraces. The HIV-PCR was positive and 
the infant was started on antiretroviral treatment during 
hospitalisation.
None of the 18 pertussis cases had a fatal outcome. Five 
children were still coughing for one to two months after 
the diagnosis. To the authors’ knowledge, all the children 
eventually recovered.
With regard to HIV co-morbidity, five (27.8%) children 
tested positive with PCR and all required hospitalisation. 
Three of them were younger than 10 weeks of age and the 
other two were four and seven months old respectively. 
Two of the younger infants needed ICU admission. The 















General ward 2 22 days R2 400 R52 800 R26 400
Public sector
General ward 8 147 days R678 R99 666 R12 458
ICU 5 88 days R2 200 R193 600 R38 720
Total 15 R346 066
*Information as quoted by private and public hospital administration for 2008 (personal 
communication).
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older two children presented with a lobar pneumonia. The 
four-month-old child had never been immunised, while the 
seven-month-old had received only the first two doses of 
vaccine.
Discussion
According to statistics available from the Department of 
Health, 94 cases of pertussis were reported in South Africa 
for the period 1999–2005. Most cases were infants younger 
than one year, and the majority occurred in the Western 
Cape and Gauteng. Approximately a quarter of the cases 
were diagnosed during February.8 No national figures were 
published after 2005. No cases were reported in the Free 
State province during 1998–2002, and after this period no 
records are available (personal communication, Free State 
Department of Health). A recent Communicable Diseases 
Communiqué of the National Institute of Communicable 
Diseases (NICD) and the NHLS reported two cases of infants 
with pertussis, one six weeks and the other 10 weeks of 
age, who were part of a cluster of pertussis cases. It was 
not mentioned in which province these children resided.9 
The vaccination coverage in South Africa has been reported 
to be 97% for the third pertussis vaccine (DTP).2
The WHO recommended that an incidence of pertussis of 
less than one case per 100 000 population should have 
been achieved in Europe by 2000. Globally, only Japan 
has achieved this target. Other developed countries with 
low national incidences are the USA with 2.7, France with 
3.4 and the United Kingdom with 4.0. There has been a 
resurgence in other developed countries, with reported 
incidences of 10–30 in Canada, 22–58 in Australia and 180 
in Switzerland. More cases occurred in the older age groups 
in these countries despite high immunisation rates in the 
paediatric population.10
In 2005, the WHO reported a total number of 17.6 million 
cases of pertussis. It is thought that the worldwide 
resurgence of pertussis could be attributed to the following:
• Waning of natural and vaccine-induced immunity.
• Lack of natural boosting.10 
• The emergence of new bacterial toxin variants.11,12
It is estimated that 71% of the global burden of pertussis 
occurs in developing countries.2 However, no accurate 
figures are available for Africa, Asia or Latin America.2,13 A 
recent study from Argentina reported a rising incidence of 
pertussis since 1997, with a peak in 2005 of 5.7 per 100 000 
population.11 Although the WHO reports the number of 
pertussis cases per region of the world, it is estimated that 
only 5 to 25% of cases are actually reported.10 In 2001, the 
Global Pertussis Initiative (GPI) was established to monitor 
the pertussis problem on a worldwide basis and to advise 
on control measures.14
The incidence of pertussis, for the 12 months studied, 
for Bloemfontein and surrounding areas was calculated 
to be 2.1 cases per 100 000 population. This is based 
on 18 cases in 12 months in an estimated population of 
840 000.15 This is likely to be a small proportion of the total 
number of people infected with B. pertussis. It is estimated 
that the true incidence is three- to fourfold the reported 
incidence in developed countries, and globally up to 100-
fold the reported incidence.2,10 This situation is due to the 
lack of surveillance; underreporting (especially in the older 
population), and difficulty in making the diagnosis. Because 
only those children ill enough to present to a hospital 
were diagnosed, it is certain that many cases have gone 
undiagnosed.
No confirmed adult case of pertussis was either reported 
or investigated by the local public and private diagnostic 
medical microbiology laboratories. It is reported that more 
than 20% of pertussis cases occur in adolescents and 
adults, and up to a quarter of adults with a prolonged cough 
have pertussis.3,16 In the post-vaccination era in developed 
countries, pertussis has become a disease of adolescents 
and adults.10 We are not sure whether this case series has 
been an outbreak or whether the disease is at the peak of one 
of its cyclical (changing incidence over years) or seasonal 
(changing incidence within a year) phases, or whether it has 
not been recognised and diagnosed.17 A seasonal increase 
has been recorded to occur in South Africa in the first three 
months of the year.3,8,10 At the time of this pertussis cluster, 
there was an acceptable vaccination coverage of just below 
90% in the district.
The diagnosis of pertussis is initially based on clinical 
characteristics, which includes a cough lasting for 
longer than two weeks.4 In South Africa, with a very high 
incidence of tuberculosis and HIV infection, pertussis is 
easily overlooked. Unless the history of a whoop, post-
tussive vomiting or paroxysms of coughing is specifically 
asked for, or the physician has the opportunity to observe 
an episode, pertussis may be missed. Tuberculosis and 
respiratory infections caused by Mycoplasma, Chlamydia, 
B. parapertussis and B. bronchiseptica and viral infections, 
caused by adenovirus, respiratory syncitial virus, human 
metapneumovirus, parainfluenza and influenza viruses, 
may also present with coughing of prolonged duration. 
Other causes also associated with protracted coughing 
include foreign bodies in the airways, asthma and 
bronchiectasis, which are common in South Africa. In our 
series, coughing for two weeks was never present in the 
younger prevaccinated infants. These are the children most 
at risk and most severely affected. A history of exposure to 
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a coughing adolescent or adult contact could be helpful in 
the diagnosis.
To diagnose more cases of pertussis in the community, 
it is necessary to have access to resources to confirm a 
suspected case. The Bordetella PCR is available in the 
public health sector via the NHLS laboratories, from where 
the specimens are sent to Johannesburg. Specimens 
need to reach the laboratory within 12 days of collection. 
The result should be available within three working days 
of receipt at the testing laboratory. Thus the Bordetella 
PCR is accessible anywhere in South Africa. The cost of a 
Bordetella PCR in 2009 was R458 and R562 in the public 
and private sectors, respectively.
Thick Dacron® or rayon swabs are generally available in 
the public sector health facilities. Thinner swabs are easier 
to use in children, as they can be inserted deeper into 
the nasopharyngeal cavity, improving the yield of positive 
results. This justifies the cost of R9 for the thinner swabs as 
opposed to the standard swabs at 30 cents (based on 2009 
information).
A pertussis antibody test, available in only one laboratory 
in South Africa, is not useful for diagnostic purposes 
early in the disease.5 Culture is the gold standard but is 
not done routinely. Bordetella is very difficult to culture 
and the possibility of isolating this fastidious organism 
decreases over time. Collection of the specimen should 
be at the bedside using cough plates, which is technically 
difficult to perform, especially in children.3 Furthermore, it 
is not always feasible to have culture medium available, as 
it has a short shelf life. The cost of the culture medium is 
R17.40 per plate, and isolation costs are approximately R80 
(based on 2009 information). However, it would be useful 
to culture existing circulating Bordetella organisms to type 
the strain for surveillance, as well as for future vaccine 
manufacturing.11,12
Laboratory confirmation of pertussis is recommended and 
is probably cost-effective. A definitive diagnosis always 
influenced the management of the children in this series, 
and was helpful in limiting further investigations. Antibiotic 
therapy was changed to a macrolide, inappropriate 
treatment was terminated and contacts were given 
prophylactic treatment to limit the spread of the disease. 
This outbreak shows that the main burden of severe disease 
in pertussis occurs among young infants.7 All children 
admitted to the ICU in this series were aged nine weeks or 
younger, and most children (11 of 18; 61.1%) were younger 
than three months of age.11 The female predominance in this 
series has been documented in other studies, but currently 
no explanation for this observation has been proposed.18
In this small group, HIV-positive cases did not seem to be 
more common in the children affected by pertussis than in the 
population of children admitted to hospital, and HIV infection 
also did not adversely affect the outcome. An unanswered 
question is whether trimethoprim-sulfamethoxazole used 
as prophylaxis in HIV-infected children reduces their risk for 
B. pertussis infection or severe illness.
Pertussis is costly. There are direct medical costs (doctors’ 
fees, hospitalisation, laboratory and radiological fees), as 
well as indirect costs (lost working days, travel costs). In a 
study among the Dutch population, infants accounted for 
only 5% of pertussis cases, but generated 50% of the costs 
pertaining to the management of the disease.19,20
Several suggestions have been made in recent medical 
literature for the prevention of the re-emergence of pertussis. 
Reduction of the incidence of pertussis in prevaccinated 
infants is the main objective. These proposals, listed below, 
should be discussed and considered in order to implement 
a new pertussis vaccination strategy for South Africa.
• Pre-term infants must be vaccinated according to their 
chronological age.21
• Revaccination at age four to five years is routinely done 
in North America, and has also been recommended by 
the GPI.6,22 However, a Dutch study concluded that a 
pre-school booster is not a cost-effective strategy.19
• Vaccination of adults could be considered.21–23 Although 
the cost of the disease is carried mainly by infants, the 
GPI suggests that the most effective method to reduce 
the main burden of the disease would be to focus on 
reducing the disease among the adult population.20
• Vaccination of adults in close contact with newborns is 
regarded as the most effective strategy. This is the so-
called cocoon strategy, which involves the vaccination 
of parents, close household contacts and healthcare 
workers.6,22
• Maternal immunisation in pregnancy would partly protect 
the infant from the time of birth, except for premature 
babies.7 Infants would still be susceptible until their 
own immunity is induced. There are insufficient data on 
the safety of vaccination (DTaP in which the pertussis 
component is acellular) in pregnancy, and it is now 
advised that mothers be vaccinated in the postpartum 
period.6,24
• Vaccination of adolescents is an important 
consideration, as they are a significant reservoir of 
infection. Adolescents could be reached through high 
school immunisation programmes.2,6,11,16,25,26
• Vaccination of newborns has been suggested.19 
However, neonatal vaccination is no longer regarded as 
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an option, as the acellular pertussis vaccine has been 
found to interfere with an adequate antibody response 
to other infant vaccines up to 18 months of age.27,28
• Finally, revaccination of HIV-infected children on 
antiretroviral treatment could be considered in order to 
boost their antibody levels.29
Conclusion
Awareness of pertussis needs to be rekindled. Data need 
to be collected nationally, also in older children, adults and 
the elderly, to determine the true incidence of pertussis. An 
assessment of pertussis vaccination needs to be formulated 
to address persistent pertussis infections. Broader vaccine 
coverage in the general population would probably be 
cost-effective. 
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